Jan 2014
Vol. 12
No. 1

Original Report

Reviews

Community Translations

  • Community Translations

    Afatinib in metastatic NSCLC with mutations

    In July 2013, afatinib was approved by the US Food and Drug Administration for first-line treatment of patients with metastatic non–small-cell...

Feature

From the Editor